INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.

Tyra Biosciences shares fell $4.72, or 17.66%, to $22.01 on September 9 after initial Phase 2 SURF302 data for dabogratinib showed Grade 3 treatment-emergent adverse events in 14% of the 60 mg once-daily cohort and 9% of the 50 mg cohort. Pomerantz LLP is investigating whether Tyra and certain officers or directors engaged in securities fraud or other unlawful practices. The safety findings and resulting stock decline create potential litigation and clinical-development risks for Tyra.

Analysis

The litigation notice is not itself a fundamental catalyst; it is a predictable aftershock of a sharp data-driven selloff and should not be treated as incremental evidence of misconduct. The investable issue is whether the adverse-event profile constrains dose selection, duration of therapy, enrollment, or regulatory positioning in a lower-risk bladder-cancer setting where the tolerability bar is materially higher than in metastatic oncology. If the eventual selected regimen cannot demonstrate a clearly favorable benefit-risk profile, TYRA faces a lower probability of differentiated commercial positioning and a longer, more capital-intensive path to registrational value.

Near term (days to weeks), class-action headlines can sustain retail and event-driven selling but usually have limited standalone valuation effect absent an SEC inquiry, restatement, or discovery of disclosure failures. The more relevant 1-3 month catalyst is management's disclosure of response durability, discontinuation rates, dose reductions, and the rationale for the recommended Phase 3 dose; those details determine whether the market reprices the program as dose-optimization noise or a therapeutic-index problem. Watch cash runway and planned trial spend: a delayed or redesigned pivotal path would increase dilution risk, which is especially punitive for a single-asset-weighted clinical biotech.

Contrarianly, the initial reaction may over-discount safety if higher-grade events are manageable, reversible, and concentrated in a dose cohort that will not advance. However, a long is premature without patient-level context versus efficacy and discontinuation data. The asymmetry remains negative if subsequent updates reveal treatment discontinuations or inadequate durability, because the addressable population is comparatively less willing to accept systemic toxicity; a clean dose-selection update could instead drive a sharp short-covering rally from depressed positioning.

Key Decisions for Investors

• No immediate directional position solely on the law-firm announcement; treat it as non-fundamental noise unless TYRA discloses a formal regulatory investigation, material insurance/legal reserve, or prior-data disclosure inconsistency.
• Maintain a 1-3 month short/watch bias in TYRA only if follow-up materials show Grade 3 events accompanied by meaningful discontinuations, dose reductions, or weak durability. Use a post-data bounce for entry rather than chasing the initial gap; cover if management identifies a lower dose with preserved activity and no material discontinuation burden.
• For portfolios able to trade biotech event risk, consider a defined-risk bearish structure around the next clinical or dose-selection update—long TYRA puts or put spreads rather than naked short exposure—because favorable dose optimization could produce a 25%+ rebound in a thin clinical-stage name.
• Set an alert for cash-runway guidance and pivotal-trial timing. A trial delay, expanded safety cohort, or financing announced within the next two quarters would reinforce downside through dilution; unchanged timing plus convincing efficacy/safety separation would falsify the bearish thesis.